Smart Library
Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.
New to hirudotherapy? Start here
This library indexes the full evidence base. For orientation, begin with the core guides:
Filters
Evidence level
Showing 5 of 730 entries. Refine via URL query params.
Conditions
3Metabolic Syndrome (Investigational Adjunct)
Tier CInvestigational adjunct to lifestyle modification in metabolic syndrome; no clinical study in metabolic syndrome identified; weight loss, dietary modification, and pharmacotherapy remain primary.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Tier CInvestigational adjunct in NAFLD/MASLD; no human clinical study identified; weight loss, dietary modification, and resmetirom remain primary.
Vascular Cognitive Impairment (Highly Investigational)
Tier CHighly investigational; no clinical study of leech therapy with cognitive outcomes was identified; vascular risk-factor management (BP, lipids, antiplatelet, lifestyle) remains primary.
Compounds
2Leech / LSE Flap-Survival VEGF Induction (Rat)
Dorsal random skin-flap rat model: medicinal leech application + leech saliva extract injection both increase VEGF, neovascularisation + reduce necrosis vs control — Ünal 2025.
RK22 Antimicrobial Peptide (MRSA-Active)
11-mer antimicrobial peptide RK22 from Hirudinaria manillensis salivary-gland transcriptome — Lu 2023 demonstrates MRSA killing + biofilm eradication.